Edward Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edward Kim has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Fischman
Department of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
11 shared publications - Francis S. Nowakowski
Division of Vascular and Interventional Radiology, Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, United States of America
8 shared publications - Rahul S. Patel
Mount Sinai Medical Center
6 shared publications - Robert A. Lookstein
Icahn School of Medicine at Mount Sinai
6 shared publications Francis S. Nowakowski
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
5 shared publicationsRahul S. Patel
Division of Interventional Radiology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 12th Floor, New York, NY, 10029
4 shared publications
Latest Publications
- 28 October 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- p. 1-22
Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma
- 28 October 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- p. 1-22
Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma
- 3 October 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 38 (1)
A 23-Year Single-Center Experience with Elective Transcatheter Coil Embolization of Unruptured Splenic Artery Aneurysms
- 3 October 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 38 (1)
A 23-Year Single-Center Experience with Elective Transcatheter Coil Embolization of Unruptured Splenic Artery Aneurysms
- 1 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Liver Transplantation for Hepatocellular Carcinoma
Objective: To establish the significance of complete pathologic response (cPR) on survival and locoregional treatment outcomes in a large US cohort. Background: cPR in hepatocellular carcinoma (HCC) is associated with improved post–liver transplant (LT) outcomes. cPR rates, modality-specific differences, and predictors remain undefined. Materials and Methods: Patients were identified from the United Network for Organ Sharing (UNOS) database (2012–2024). cPR was defined as the absence of a viable tumor on explant pathology. Logistic regression identified predictors of cPR, Fine-Gray models estimated the incidence of cPRand Kaplan-Meier analysis assessed survival. Results: Among 7398 LT recipients, 2167 (29.3%) achieved cPR. Imaging–pathology concordance was poor (30.5%), with imaging overestimating response in 42.6% of cases (κ=0.17, P 18 vs. P P <0.001). Conclusions: Nearly one-third of LT recipients with HCC achieved cPR, which was associated with improved survival. Y-90 was independently associated with higher cPR rates, particularly when administered early and among patients with higher tumor burden.
- 1 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Liver Transplantation for Hepatocellular Carcinoma
Objective: To establish the significance of complete pathologic response (cPR) on survival and locoregional treatment outcomes in a large US cohort. Background: cPR in hepatocellular carcinoma (HCC) is associated with improved post–liver transplant (LT) outcomes. cPR rates, modality-specific differences, and predictors remain undefined. Materials and Methods: Patients were identified from the United Network for Organ Sharing (UNOS) database (2012–2024). cPR was defined as the absence of a viable tumor on explant pathology. Logistic regression identified predictors of cPR, Fine-Gray models estimated the incidence of cPRand Kaplan-Meier analysis assessed survival. Results: Among 7398 LT recipients, 2167 (29.3%) achieved cPR. Imaging–pathology concordance was poor (30.5%), with imaging overestimating response in 42.6% of cases (κ=0.17, P 18 vs. P P <0.001). Conclusions: Nearly one-third of LT recipients with HCC achieved cPR, which was associated with improved survival. Y-90 was independently associated with higher cPR rates, particularly when administered early and among patients with higher tumor burden.
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (3)
Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90 Y Radioembolization with Immunotherapy in HCC
New strategies combining yttrium 90 ( 90 Y) radioembolization and immune checkpoint inhibitor therapy for treatment of advanced-stage hepatocellular carcinoma show promising safety and improved tumor response rates, with 90 Y radioembolization modulating the tumor immune microenvironment and enhancing responsiveness to immunotherapy.
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (3)
Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90 Y Radioembolization with Immunotherapy in HCC
New strategies combining yttrium 90 ( 90 Y) radioembolization and immune checkpoint inhibitor therapy for treatment of advanced-stage hepatocellular carcinoma show promising safety and improved tumor response rates, with 90 Y radioembolization modulating the tumor immune microenvironment and enhancing responsiveness to immunotherapy.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Hepatology
BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as the degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic–locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. In conclusion, BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
- 7 August 2026
- Published by Wolters Kluwer Health in Hepatology
Open AccessBEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as the degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic–locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. In conclusion, BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
- Top Cited Papers
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (2) , e251923
Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (2) , e251923
Top Cited PapersConsortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
- 23 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107852
Authors’ Reply: Histopathologic Outcomes after Transarterial Chemoembolization and Transarterial Radioembolization
- 23 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107852
Authors’ Reply: Histopathologic Outcomes after Transarterial Chemoembolization and Transarterial Radioembolization
- 1 July 2025
- Vol. 316 (1) , e240333
The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy.
Transarterial radioembolization (TARE) is an image-guided cancer treatment that delivers microspheres carrying radiation-emitting isotopes, such as yttrium 90 (90Y), to liver malignancy via the hepatic arteries. Historically a palliative therapy for advanced liver cancer, TARE with 90Y has evolved via the segmental delivery of 90Y microspheres with ablative intent, known as radiation segmentectomy. The purpose of radiation segmentectomy is to deliver high radiation doses to targeted hepatic segments, limiting the volume of normal hepatic parenchyma exposed to radiation. Radiation segmentectomy is characterized by high, sustained response rates and high rates of explant necrosis. Currently, radiation segmentectomy is a recognized treatment option for patients with Child-Pugh class A liver function and solitary hepatocellular carcinoma that is 8 cm or smaller in size. It can be applied for hepatic metastases not amenable to resection or thermal ablation. Advancements in patient selection, technique, and radiation dosimetry for radiation segmentectomy have redefined the goal of TARE as a curative therapy. With improved dosimetry and patient selection, it has become more common to observe early responses at posttreatment imaging after radiation segmentectomy, even complete response within the first month of treatment. This article reviews the history of radiation segmentectomy, its expanding applications, and future directions.
- 1 July 2025
- Vol. 316 (1) , e240333
The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy.
Transarterial radioembolization (TARE) is an image-guided cancer treatment that delivers microspheres carrying radiation-emitting isotopes, such as yttrium 90 (90Y), to liver malignancy via the hepatic arteries. Historically a palliative therapy for advanced liver cancer, TARE with 90Y has evolved via the segmental delivery of 90Y microspheres with ablative intent, known as radiation segmentectomy. The purpose of radiation segmentectomy is to deliver high radiation doses to targeted hepatic segments, limiting the volume of normal hepatic parenchyma exposed to radiation. Radiation segmentectomy is characterized by high, sustained response rates and high rates of explant necrosis. Currently, radiation segmentectomy is a recognized treatment option for patients with Child-Pugh class A liver function and solitary hepatocellular carcinoma that is 8 cm or smaller in size. It can be applied for hepatic metastases not amenable to resection or thermal ablation. Advancements in patient selection, technique, and radiation dosimetry for radiation segmentectomy have redefined the goal of TARE as a curative therapy. With improved dosimetry and patient selection, it has become more common to observe early responses at posttreatment imaging after radiation segmentectomy, even complete response within the first month of treatment. This article reviews the history of radiation segmentectomy, its expanding applications, and future directions.